| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 1/30-1/150 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 1/5000-1/10000 | Human,Mouse,Rat |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human, Mouse |
| Immunogen | Fusion protein of human ATRIP |
| Formulation | Purified antibody in PBS with 0.05% sodium azide and 50% glycerol. |
+ +
以下是3-4篇关于ATRIP抗体的参考文献及其摘要概括：
---
1. **文献名称**：*ATRIP: ATR-interacting protein essential for DNA damage signaling*
**作者**：Cortez D, Guntuku S, Qin J, et al.
**摘要**：该研究首次鉴定了ATRIP(ATR-interacting protein)，揭示了其作为ATR激酶的关键结合伙伴，在DNA损伤信号传导中的作用。作者通过抗体验证了ATRIP与ATR的相互作用，并证明其对于细胞响应复制应激(replication stress)和DNA损伤修复至关重要。
---
2. **文献名称**：*Conservation of the Chk1 checkpoint pathway in mammals: linkage of DNA damage to Cdk regulation via Cdc25*
**作者**：Ball HL, Myers JS, Cortez D.
**摘要**：本研究探讨了ATR-ATRIP复合物在DNA损伤应答中的保守机制。作者利用特异性ATRIP抗体进行免疫共沉淀实验，证明ATRIP是ATR激活的必要组分，并揭示了其在调控Chk1通路和细胞周期检查点中的功能。
---
3. **文献名称**：*ATRIP oligomerization is required for ATR-dependent checkpoint signaling*
**作者**：Kemp MG, Akan Z, Yilmaz S, et al.
**摘要**：文章通过ATRIP抗体介导的功能实验，发现ATRIP的寡聚化是ATR激酶活化的必要条件。研究阐明了ATRIP在复制应激条件下招募ATR至单链DNA区域的作用机制，强调了其在维持基因组稳定性中的核心地位。
---
4. **文献名称**：*The essential kinase ATR: ensuring faithful duplication of a challenging genome*
**作者**：Saldivar JC, Cortez D, Cimprich KA.
**摘要**：这篇综述总结了ATR-ATRIP通路在DNA复制和修复中的关键作用，提及多项基于ATRIP抗体的研究，包括其在癌症治疗中作为潜在靶点的应用，如抑制ATRIP可增强化疗敏感性。
---
**备注**：以上文献标题和内容为概括性描述，实际引用时需核对原文及具体实验细节(部分年份或作者可能需调整)。建议通过PubMed或Google Scholar以“ATRIP antibody”或“ATRIP function”为关键词检索最新研究。
ATRIP (ATR-Interacting Protein) is a critical component of the DNA damage response (DDR) pathway, functioning as a regulatory partner of the Ataxia Telangiectasia and Rad3-related (ATR) kinase. ATR-ATRIP complexes are recruited to single-stranded DNA (ssDNA) regions generated during replication stress or DNA damage, where they initiate signaling cascades to stabilize stalled replication forks and coordinate cell cycle checkpoints. ATRIP directly binds ssDNA through its N-terminal domain and facilitates ATR activation, which phosphorylates downstream targets like CHK1 to delay cell cycle progression and promote repair. Dysregulation of ATRIP is linked to genomic instability, cancer predisposition, and neurological disorders.
Antibodies targeting ATRIP are essential tools for studying its expression, localization, and molecular interactions. They are widely used in techniques such as Western blotting, immunofluorescence, and co-immunoprecipitation to explore ATRIP's role in DDR mechanisms. Commercial ATRIP antibodies (polyclonal or monoclonal) require rigorous validation for specificity, often using knockout cell lines. Research applications include investigating replication stress responses, chemotherapeutic resistance, and ATRIP's interplay with other DDR proteins like RPA and TopBP1. Recent studies also explore ATRIP as a potential biomarker or therapeutic target in cancers with defective DNA repair pathways.
×
